Michael. W. Fried

Michael. W. Fried's AcademicInfluence.com Rankings

Michael. W. Fried

Philosophy

#8225

World Rank

#11564

Historical Rank

Logic

#5258

World Rank

#6643

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Michael. W. Fried Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael. W. Fried's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. (2002) (6617)
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011) (1454)
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) (1285)
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) (1153)
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. (2000) (959)
Response-guided telaprevir combination treatment for hepatitis C virus infection. (2011) (799)
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2014) (783)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (2015) (761)
Side effects of therapy of hepatitis C and their management (2002) (744)
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. (2015) (694)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. (2005) (569)
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. (1995) (566)
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. (2006) (495)
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. (2017) (484)
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (2014) (469)
Liver transplantation for acute liver failure from drug induced liver injury in the United States (2004) (439)
Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. (1994) (381)
Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C (2001) (343)
A pilot study of ribavirin therapy for chronic hepatitis C (1992) (300)
Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study (2013) (295)
Side effects of therapy of hepatitis C and their management (2002) (293)
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response (2007) (289)
Side effects of therapy for chronic hepatitis C. (2003) (273)
Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function (2016) (267)
Ribavirin as Therapy for Chronic Hepatitis C (1995) (263)
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. (2014) (252)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B (2008) (247)
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. (2007) (216)
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. (2011) (206)
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. (2016) (206)
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. (2010) (188)
Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial (2005) (179)
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. (2016) (178)
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. (1995) (175)
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment (2017) (174)
Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract (2008) (173)
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. (2001) (167)
Ribavirin potentiates interferon action by augmenting interferon‐stimulated gene induction in hepatitis C virus cell culture models (2011) (162)
Barriers to hepatitis C treatment (2012) (161)
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. (2012) (142)
Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C (2010) (137)
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study (2014) (135)
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study (2017) (134)
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies (2015) (133)
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). (2002) (133)
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B (2002) (131)
Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response (2011) (124)
Current therapy for hepatitis C: pegylated interferon and ribavirin. (2003) (122)
Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study (2001) (117)
Increasing Hepatitis C Virus RNA Levels in Hemophiliacs: Relationship to Human Immunodeficiency Virus Infection and Liver Disease (1994) (117)
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure (2018) (116)
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. (2007) (110)
Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network (2015) (110)
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care (2013) (109)
Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States (2004) (107)
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. (2005) (107)
R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin (2008) (103)
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. (2001) (101)
Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? (1998) (100)
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. (2015) (98)
Social Stigmatization and Hepatitis C Virus Infection (2006) (92)
The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity (2008) (91)
Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA (1995) (87)
Sequence Heterogeneity of TT Virus and Closely Related Viruses (2000) (84)
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States (2020) (82)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. (1995) (80)
Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin (2008) (80)
Severe villus atrophy and chronic malabsorption induced by azathioprine. (2003) (79)
Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin (2002) (77)
Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. (1992) (77)
Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial (2004) (76)
Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. (2004) (75)
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study (2016) (75)
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. (2015) (75)
Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C: Results of the Virahep-C Study (2009) (74)
A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. (1993) (71)
American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. (2017) (70)
Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin (2008) (70)
Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C (2005) (66)
A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment (2011) (65)
Assessing the Validity of Self-Reported Medication Adherence in Hepatitis C Treatment (2007) (64)
Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome (2001) (63)
PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL (2013) (59)
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin (2007) (58)
High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities (2007) (58)
Management of hepatitis C in the hemophilia patient. (1999) (57)
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. (2012) (57)
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype (2000) (56)
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection (2006) (54)
Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C (2011) (54)
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. (2003) (53)
Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential (2014) (52)
Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C (2013) (52)
All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database (2017) (50)
Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests (2001) (49)
LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target (2015) (48)
Barriers to accessing care in patients with chronic hepatitis C: the impact of depression (2010) (48)
Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial (2019) (48)
Hepatitis B and C and renal failure. (2001) (48)
Natural history and disease manifestations of hepatitis C infection. (2000) (47)
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B‐induced end stage liver disease (2006) (47)
Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
Therapy of chronic hepatitis B with a 6-month course of ribavirin. (1994) (42)
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. (2016) (41)
Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis (1993) (40)
O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience (2015) (38)
A pilot study of 2′,3′‐dideoxyinosine for the treatment of chronic hepatitis B (1992) (35)
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
Chronic hepatitis B: a critical appraisal of current approaches to therapy. (2006) (34)
Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues (2012) (33)
2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL (2012) (32)
Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial (2013) (32)
Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials (2014) (32)
Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study. (2019) (31)
High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study (2016) (30)
Viral factors affecting the outcome of therapy for chronic hepatitis C. (2004) (30)
993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (30)
1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT (2011) (29)
Thursday, 24 AprilParallel Session 1: HEPATITIS C THERAPY7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (29)
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir (2015) (29)
50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B (2006) (29)
Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection (2014) (29)
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. (2012) (28)
Creatine kinase isoenzymes in the diagnosis of intestinal infarction (1991) (28)
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? (2013) (27)
Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy. (2019) (26)
Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence (2013) (26)
Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. (2011) (26)
High relapse rate seen at week 72 for patients treated with R1626 combination therapy (2008) (24)
Advances in therapy for chronic hepatitis C. (2001) (24)
Orthotopic liver transplantation for biliary papillomatosis (2001) (24)
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. (2019) (24)
Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C (2004) (23)
MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure (2017) (23)
Internal biliary stenting in orthotopic liver transplantation (2000) (22)
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study (2018) (22)
881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS (2013) (21)
Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
Unexpected Maintenance of Hepatitis C Viral Diversity following Liver Transplantation (2012) (21)
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies (2015) (20)
1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN (2010) (20)
1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2011) (19)
Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: A matched, case‐controlled study (2002) (19)
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis (2018) (18)
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (2018) (18)
Psychiatric symptoms during interferon treatment for hepatitis C:experiences from a tertiary care hepatology centre (2008) (18)
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C (2012) (18)
Factors Associated with Readmission in the US Following Hospitalization with COVID-19 (2021) (17)
Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. (2006) (17)
Diagnostic testing for hepatitis C: practical considerations. (1999) (17)
MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure (2017) (17)
TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY (2011) (17)
Elevated AST‐to‐platelet ratio index is associated with increased all‐cause mortality among HIV‐infected adults in Zambia (2015) (17)
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection (2019) (17)
Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation (2020) (16)
Optimizing treatment regimens in hepatitis C. (2006) (16)
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy (2020) (16)
Plasma levels of growth‐related oncogene (CXCL1‐3) associated with fibrosis and platelet counts in HCV‐infected patients (2015) (16)
Guidelines for stopping therapy in chronic hepatitis C (2004) (16)
1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2012) (15)
Hepatitis C and alcohol: fundamental and translational research directions. (2003) (15)
Persistent Portosystemic Shunts After Liver Transplantation Causing Episodic Hepatic Encephalopathy (2010) (15)
An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots (2018) (15)
Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients (2013) (15)
Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. (2017) (14)
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia (2015) (14)
11 IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONa-2A AND RIBAVIRIN IN PILLAR STUDY (2011) (14)
The role of triple therapy in HCV genotype 1‐experienced patients (2011) (14)
Modified piggyback technique for adult orthotopic liver transplantation. (2000) (13)
Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort (2018) (13)
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. (2017) (13)
Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C (2012) (13)
A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy (1999) (13)
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. (2017) (12)
Prevalence and factors associated with statin use among patients with non-alcoholic fatty liver disease in TARGET-NASH. (2021) (12)
Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. (2009) (12)
943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial (2012) (11)
What’s Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment (2017) (11)
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals (2019) (11)
1168 IL28B GENETIC VARIATION ASSOCIATED WITH EARLY VIRAL KINETICS AND SVR IN HCV GENOTYPE 1 THE VIRAHEP-C STUDY (2010) (10)
Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B (2017) (10)
49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB) (2006) (9)
Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity (2015) (9)
522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR) (2004) (9)
A multicenter, randomized trial of daily, high dose interferon-alpha 2b for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotype (1998) (9)
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis (2019) (9)
A real‐world observational cohort of patients with primary biliary cholangitis: TARGET‐primary biliary cholangitis study design and rationale (2018) (9)
Hepatitis C infection with normal liver chemistry tests. (2008) (8)
P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study (2015) (8)
Hepatitis C viral infection in patients with hemophilia and hemolytic disorders (2012) (8)
Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-NaïVE Patients Regardless of Race or Ethnicity (2011) (8)
Patient‐reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross‐sectional analysis (2020) (8)
761 Expanding the donor pool by transplanting cadaveric livers from older donors: an analysis of patient and graft survival by donor age from the United Network for organ sharing database (2003) (7)
Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Analysis (2016) (7)
Treatment options of patients with chronic hepatitis C who have failed prior therapy (2016) (7)
Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem (2016) (6)
Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. (2019) (6)
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis (2021) (6)
The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. (2018) (6)
Idiopathic CD4+ T‐lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men (1995) (6)
Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: Results from the PROP UP study (2021) (6)
995 A dynamic model to predict sustained virological response to combination peginterferon alfa-2A (40KD) (PEGASYS(®)) and ribavirin (COPEGUS(®)) therapy in patients with chronic hepatitis C (2003) (5)
764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study (2014) (5)
Controversies in hepatitis C therapy: Reactivation of hepatitis B virus (2017) (5)
“If I Get Cured, My Whole Quality of Life Will Change”: Patients’ Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C (2021) (5)
Case studies of the hepatitis B patient: a panel discussion. (2000) (5)
P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis (2015) (5)
Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study (2017) (4)
Safety and Efficacy of New Daa Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-Target Study (2016) (4)
956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study (2019) (4)
P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS (2014) (4)
Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard inferferon alfa-2a (2001) (4)
Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (PEGASYSTM) and thrice weekly interferon alfa-2a (RoferonTM) in patients with chronic hepatitis C without cirrhosis (2000) (4)
Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C (2018) (4)
Chronic hepatitis B virus monoinfection at a university hospital in Zambia (2018) (4)
HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape (2015) (4)
Hepatitis C: Current options for nonresponders to peginterferon and ribavirin (2008) (4)
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV (2021) (4)
Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentretreatment Protocol (2016) (3)
Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study (2021) (3)
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV‐infected patients regardless of DPP4 activity (2016) (3)
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (2021) (3)
Clinical Practice Guidelines : Management of hepatitis C virus infection European Association for the Study of the Liver ⇑ (2013) (3)
Real‐world evidence in hepatocellular carcinoma (2021) (3)
A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy (2018) (3)
Incidence of and predictors for direct acting antiviral treatment failure among 3909 hepatitis C genotype 1 infected adults: real world outcomes from HCV TARGET (2017) (3)
17 Hepatitis C and renal disease (2000) (3)
Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial (2019) (3)
1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis (2015) (3)
Twice Daily Dosing of Telaprevir for Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Infection (2014) (3)
THU-181-Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study (2019) (3)
8 Patient and graft survival after adult living donor liver transplantation compared to cadaveric liver transplantation in patients with chronic hepatitis C: an analysis of the United network for organ sharing database (2003) (3)
Sequence heterogeneity within three different regions of the hepatitis G virus genome. (1999) (2)
The FDA, bridging data, and hepatitis C (2013) (2)
Management of newly diagnosed hepatitis C virus infection. (2003) (2)
Quantitation of Pretreatment Serum IP-10 Improves the Predictive Value of an IL28B Gene Polymorphism for Hepatitis C Treatment Response (2011) (2)
Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy (2020) (2)
Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1 (2015) (2)
1117 Increasing liver-related mortality in incarcerated populations (2003) (2)
Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C (2017) (2)
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". (2019) (2)
Treatment Effect and Resistance Profiles were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination Regimen (2011) (2)
O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY (2014) (2)
Safety and efficacy of elbasvir and grazoprevir with or without ribavirin for the treatment of hepatitis C virus genotype 1: results of the hepatitis C virus-TARGET study (2017) (1)
HCV: The Journey from Discovery to a Cure: Volume II (2019) (1)
PANTOPRAZOLE REDUCES THE SIZE OF POST-BANDING ULCERS AFTER ELECTIVE ENDOSCOPIC VARICEAL BAND LIGATION: A RANDOMIZED, CONTROLLED TRIAL (2004) (1)
550 Hemophilic siblings with chronic hepatitis C: evidence of a genetic association with disease progression (2003) (1)
O116 HEPATITIS B SURFACE ANTIGEN (HBsAg) LEVELS DIFFER ACROSS HBV GENOTYPE AND PHENOTYPE: RESULTS FROM THE ADULT COHORT STUDY OF THE NIDDK-SPONSORED HEPATITIS B RESEARCH NETWORK (2014) (1)
388 Race, insulin resistance, visceral adiposity and hepatic steatosis in genotype 1 patients with chronic hepatitis C (2003) (1)
Su1428 Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment Protocol (2016) (1)
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation (2023) (1)
Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study (2016) (1)
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. (2019) (1)
410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS (2011) (1)
Poster Session I (PI 1–89) (2009) (1)
Speech patterns and enunciation for encephalopathy determination—A prospective study of hepatic encephalopathy (2022) (1)
THU-182-The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders (2019) (1)
Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study (2020) (1)
Parsing the guidelines on guidelines: Balancing sensibility and conflict of interest (2018) (1)
Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir. (2021) (1)
[658] OPTIMAL PRE-TREATMENT HCV-RNA LEVEL FOR PREDICTION OF SVR WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN IN GENOTYPE 1 PATIENTS: GENERALISED ADDITIVE LOGISTIC REGRESSION MODEL (GAM) ANALYSIS (2007) (0)
Sa1463 - Associations of Alcohol Consumption Motives with Depression and Pain Among Individuals with Hepatitis C (2018) (0)
1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials (2015) (0)
O121: Peg‐IFN/RBV plus second‐generation protease inhibitors (2013) (0)
25. Hepatitis C (2011) (0)
Erratum: Decreasing fibrogenesis. An immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B (Journal of Hepatology (2001) 35 (749-755) PII:S0168827801002185) (2002) (0)
Treatment of chronic hepatits C virus (HCV) infection with a modified form of Interferon alfa-2a (IFN) containing a branched, 40 kDa polyethylene glycol (PEG) moiety: virological results in patients with and without cirrhosis (1999) (0)
Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC (2018) (0)
CHOLEDOCHOCHOLEDOCHOSTOMY IN LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS (1999) (0)
Reply to authors. (2018) (0)
Comparing Oral Medicines to Treat Hepatitis C Virus -- The PRIORITIZE Study (2022) (0)
Response by Dr. Oates et al. [1] (1992) (0)
Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists (2021) (0)
OUTCOMES COMPARISON OF PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATITIS B AND HEPATITIS C (1998) (0)
Metastatic leiomyosarcoma mimicking polycystic liver disease (2002) (0)
Mo1451 - Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in Target-PBC (2018) (0)
HCV Genotype 1: How are you Managing the Non-Responders and Relapsers? A North American Perspective (2010) (0)
PREVALENCE OF LOW BONE MASS AND RISK FACTORS IN PATIENTS AWAITING LIVER TRANSPLANTATION.: Abstract# 783 Poster Board #‐Session: P40‐III (2000) (0)
There are no formulae for determining how large a sample is needed in multiple regression or any multivariate technique. (1992) (0)
492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB) (2006) (0)
Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort. (2023) (0)
322 Baseline psychosocial characteristics of participants in the virahep-C study (2003) (0)
Real-World Evidence and Hepatitis C (2019) (0)
Killing Two Birds With No Stone (2021) (0)
Reply: (2009) (0)
Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
Letters to the editor (2005) (0)
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. (2023) (0)
Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort (2018) (0)
P767 PLASMA LEVELS OF GRO ASSOCIATE WITH FIBROSIS AND PLATELET COUNTS IN HCV INFECTED PATIENTS FROM THE VIRAHEP-C COHORT (2014) (0)
Prevalence and impact of hepatitis E virus infection in the Hepatitis B Research Network cohort (2018) (0)
Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial. (2023) (0)
Safety of Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir with or without rivavirin in HCV Genotype 1-infected Patients : Results from Phase 2 a,d 3 Trails (2015) (0)
Interferon alfa-2b and ribavirin combinations is effective in patients with hemophilia and chronic hepatitis C (2003) (0)
Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1 (2015) (0)
Intensive daily high dose interferon does not overcome antiviral reslstance in African Americans with chronic hepatitis C (2001) (0)
Treatment With Silymarin for Hepatitis C Virus—Reply (2012) (0)
Viral Hepatitis: Acute and Chronic Disease (2009) (0)
CRITICAL EVALUATION OF LIVING DONORS FOR LIVING DONOR LIVER TRANSPLANTATION.: Abstract# 232 Poster Board #‐Session: P79‐I (2000) (0)
P1189 HIGH MIG (CXCL9) PLASMA LEVEL FAVORS RESPONSE TO PEGINTERFERON AND RIBAVIRIN IN HCV INFECTED PATIENTS BUT IS NOT LINKED TO DPP4 ACTIVITY (2014) (0)
Editorial: targeting liver biopsy in NAFLD—the need to expand our non‐invasive tools. Authors’ reply (2021) (0)
Internal Biliary Stenting in Orthotopic Liver Transplantation using a 6 Fr. Silastic™ Double J Ureteral Stent (1999) (0)
Primary biliary cholangitis (PBC) in the U.S.: clinical characteristics of patients enrolled in TARGET-PBC (2018) (0)
1166 THE PREDICTIVE VALUE OF IL28B GENE POLYMORPHISM FOR RESPONSE TO PEGINTERFERON AND RIBAVIRIN IS ENHANCED BY QUANTITATION OF IP-10 IN PRETREATMENT SERUM (2010) (0)
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (2018) (0)
Hepatitis C virus (HCV) genotypes 2 3 infection: A curable disease (2003) (0)
W1011 Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Silymarin (SM) Following Chronic Dosing in Patients with Chronic Hepatitis C (HCV) (2008) (0)
Response‐guided therapy for acute hepatitis C: applying concepts from chronic treatment (2011) (0)
Mo1442 - Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in Target-PBC (2018) (0)
Host liver gene regulation during chronic infection with the hepatitis C virus (2001) (0)
Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?" (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael. W. Fried?

Michael. W. Fried is affiliated with the following schools:

University of Florida
University of North Carolina at Chapel Hill

Michael. W. Fried's Academic­Influence.com Rankings

Why Is Michael. W. Fried Influential?

Michael. W. Fried's Published Works

Published Works

What Schools Are Affiliated With Michael. W. Fried?

Michael. W. Fried's AcademicInfluence.com Rankings